Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence
- First Online:
- 2.9k Downloads
There is increasing recognition of the involvement of the immune signaling molecule, tumor necrosis factor (TNF), in the pathophysiology of stroke and chronic brain dysfunction. TNF plays an important role both in modulating synaptic function and in the pathogenesis of neuropathic pain. Etanercept is a recombinant therapeutic that neutralizes pathologic levels of TNF. Brain imaging has demonstrated chronic intracerebral microglial activation and neuroinflammation following stroke and other forms of acute brain injury. Activated microglia release TNF, which mediates neurotoxicity in the stroke penumbra. Recent observational studies have reported rapid and sustained improvement in chronic post-stroke neurological and cognitive dysfunction following perispinal administration of etanercept. The biological plausibility of these results is supported by independent evidence demonstrating reduction in cognitive dysfunction, neuropathic pain, and microglial activation following the use of etanercept, as well as multiple studies reporting improvement in stroke outcome and cognitive impairment following therapeutic strategies designed to inhibit TNF. The causal association between etanercept treatment and reduction in post-stroke disability satisfy all of the Bradford Hill Criteria: strength of the association; consistency; specificity; temporality; biological gradient; biological plausibility; coherence; experimental evidence; and analogy. Recognition that chronic microglial activation and pathologic TNF concentration are targets that may be therapeutically addressed for years following stroke and other forms of acute brain injury provides an exciting new direction for research and treatment.
Accumulating evidence suggests that chronic post-stroke intracerebral microglial activation and neuroinflammation mediated by pathologic levels of tumor necrosis factor constitute new therapeutic targets that may persist for years after stroke.
Perispinal etanercept for chronic post-stroke neurological and cognitive dysfunction is an emerging treatment modality that may lead to rapid and sustained clinical improvement in this patient population.
Post-stroke disability represents a major public health problem throughout the world [1, 2]. Current drug treatments are grossly inadequate [1, 2]. The world stroke research community recognizes the urgent need for improved stroke treatments .
In February 2011, rapid improvement in cognition; improvement in chronic neurological dysfunction; and reduction in chronic, intractable post-stroke pain was noted among a series of three patients treated off-label 13, 25, and 36 months after stroke with a single dose of etanercept, administered by perispinal injection . Onset of clinical response was evident within 10 min of the etanercept dose in each patient . Each patient received a second perispinal etanercept dose at 22–26 days after the first, which was followed by additional improvement .
Rapid improvement in chronic post-stroke neurological dysfunction following perispinal etanercept
Statistically significant improvements
Increased strength, improved gait, stronger grip. Improvements in swallowing and dysarthria
Decreased muscle tone, improved range of motion, decreased shoulder pain
Improvements in cognitive testing scores and executive function
Improvements in mood, affect, and behavior. Reductions in depression and anxiety
Improvements in speech and language function
Reductions in post-stroke pain, including post-stroke shoulder pain and allodynia
Regained bladder sensation and control
Reduction in excessive emotionalism
1.1 Perispinal Administration
Lack of familiarity with the cerebrospinal venous system and the novelty of etanercept’s neurological effects may help explain the skepticism expressed by some and provides a rationale for this article . Do the etanercept stroke studies survive a rigorous analysis with respect to their suggestion of a causal association between post-stroke etanercept treatment and clinical improvement?
2 The Nine Criteria of Hill
To begin such an analysis of the etanercept stroke studies, one may apply the well known criteria laid down by the English epidemiologist and statistician, Sir Austin Bradford Hill . Hill pioneered the randomized clinical trial and was the first to demonstrate the connection between smoking and lung cancer. In his famous Presidential Address to the Royal Society of Medicine, Hill presented nine criteria for determining a causal association that would become the well known ‘Bradford Hill Criteria’ . Hill’s criteria are widely used in the evaluation of causation, have already been applied in the field of neurology, and have been recommended as a useful framework for evaluating healthcare evidence [38, 39, 40]. Hill’s nine criteria are as follows: strength of the association; consistency; specificity; temporality; biological gradient; biological plausibility; coherence; experimental evidence; and analogy.
2.1 Strength of the Association
The magnitude of the clinical improvements, as reflected by the measures that were quantitated in the 617-patient stroke cohort, including the time to walk 20 m, Montreal Cognitive Assessment, visual analog scale for pain, etc. are consistent with a strong clinical effect. The strength of the association between perispinal etanercept treatment and clinical effect is strong .
Statistically significant improvements in motor impairment, sensory impairment, cognition, aphasia, pain, and other areas of neurological dysfunction were noted, with p values consistently less than 0.001 in the 617-patient stroke cohort treated with perispinal etanercept . The consistency of the association in the perispinal etanercept stroke studies between treatment and effect is high [4, 5]. Several recent studies using basic science stroke models have documented favorable effects of tumor necrosis factor (TNF) inhibition using TNF inhibitors other than etanercept [41, 42, 43, 44]. A single study found that etanercept administered systemically was ineffective in an acute stroke model, arguing for the necessity of using specialized methods, such as perispinal delivery, to facilitate penetration of etanercept across the blood–cerebrospinal fluid barrier when treating brain disorders [7, 9, 32, 33, 34, 35, 41, 45, 46].
Neither of the etanercept stroke studies utilized a placebo control group, which limits claims of specificity. However, the clinical effects observed in the 617-patient stroke cohort after perispinal etanercept treatment were significant, and many of the results (such as rapid improvement in vision, hearing, and motor function) cannot be explained by any mechanism other than a novel treatment effect, especially considering that patients were treated a mean of 3.5 years after their stroke . The natural history of stroke recovery is well known: the great majority of the neurological recovery occurs in the first 6 months [47, 48, 49]. The spectrum of clinical improvement across domains, including improvements in motor function, cognition, sensory function, aphasia, etc., as documented in the etanercept stroke studies (see Case 1 in the 2011 etanercept stroke study, for example) can only be explained by the occurrence of a specific and novel therapeutic effect [4, 5]. The specificity of the association in the etanercept stroke studies between treatment and effect is high.
The temporal relationship between the time of etanercept administration and clinical effect is remarkably strong, since clinical improvement characteristically was observed within minutes of the first dose in both etanercept stroke studies [4, 5].
2.5 Biological Gradient
Hill’s biological gradient criteria are meant to examine whether increased exposure to the agent in question is associated with an increased biological effect. “Exposure can be characterized in different ways such as … the duration of exposure … average exposure … or cumulative exposure” . Case reports included within the etanercept stroke studies document enhanced therapeutic responses after additional doses of etanercept in certain patients [4, 5]. Subsequent clinical experience has confirmed additional neurological improvement after additional etanercept doses in multiple patients.
2.6 Biological Plausibility
“It will be helpful if the causation we suspect is biologically plausible. But this is a feature I am convinced we cannot demand. What is biologically plausible depends upon the biological knowledge of the day … In short, the association we observe may be one new to science or medicine and we must not dismiss it too light-heartedly as just too odd. As Sherlock Holmes advised Dr. Watson, ‘when you have eliminated the impossible, whatever remains, however improbable, must be the truth.’”
Evidence supporting the scientific rationale for the use of etanercept for post-stroke neurological and cognitive dysfunction
Pathophysiology and therapeutic rationale
1. Pathologic TNF is centrally involved in the pathophysiology of stroke
Rationale: Etanercept and other TNF inhibitors reduce pathologic TNF concentration
Feuerstein 1994 
Barone 1997 
Nawashiro 1997 
Kaushal 2008 
Tobinick 2011 
Siniscalchi 2014 
Etanercept and other biologic TNF inhibitors improve stroke outcome
Feuerstein 1994 
Barone 1997 
Nawashiro 1997 
Tobinick 2011 
Tobinick 2012 
Lei 2013 
King 2013 
Works 2013 
2. TNF mediates neuropathic pain
Rationale: Etanercept and other TNF inhibitors reduce neuropathic pain
Oka 1996 
Sommer 1998 
Ignatowski 1999 
Lindenlaub 2000 
Covey 2000 
Sommer 2001 
Martuscello 2012 
Ignatowski 2013 
TNF Ab or TNF siRNA reduces neuropathic pain
Etanercept reduces neuropathic pain
Lindenlaub 2000 
Covey 2000 
Sommer 2001 
Ignatowski 2013 
Sommer 2001 
Zanella 2008 
Cohen 2009 
Shen 2011 
Watanabe 2011 
Tobinick 2011 
Tobinick 2012 
Ohtori 2012 
Freeman 2013 
Sainoh 2013 
Kaufman 2013 
Coelho 2014 
3. Excess TNF is centrally involved in the pathophysiology of chronic brain dysfunction in multiple disease states: (a) cerebral malaria; (b) TBI; (c) stroke; (d) Alzheimer’s disease; (e) frontotemporal dementia; (f) post-surgery; (g) hepatic encephalopathy
Rationale: Etanercept reduces cognitive impairment in disorders associated with excess TNF
Goodman 1990 
Perry 2001 
Tarkowski 2003 
Sjogren 2004 
Tweedie 2007 
Kaushal 2008 
John 2008 
Chio 2010 
Terrando 2010 
Frankola 2011 
Butterworth 2011 
Clark 2012 
Chastre 2012 
Cheong 2013 
Chio 2013 
Miller 2013 
Etanercept reduces TNF-mediated cognitive impairment in Alzheimer’s disease, other dementias, stroke, TBI, rheumatoid arthritis, sarcoidosis, hepatic encephalopathy, post status epilepticus
Tobinick 2012 
Chen 2010 
Efferich 2010 
Bassi 2010 
Butterworth 2013 
Tobinick 2014 
4. Stroke and TBI cause chronic intracerebral glial activation and neuroinflammation
Rationale: Etanercept reduces glial activation and pathologic TNF concentration
Dubois 1988 
Myers 1991 
Pappata 2000 
Gentleman 2004 
Gerhard 2005 
Price 2006 
Kaushal 2008 
Folkersma 2011 
Ramlackhansingh 2011 
Johnson 2013 
Etanercept inhibits glial activation and neuroinflammation
Marchand 2009 
Chio 2010 
Butterworth 2011 
Shen 2011 
Chastre 2012 
Roh 2012 
Butterworth 2013 
Reviewing the evidence discussed herein, the published results of perispinal etanercept for post-stroke disability are consistent with the following: (1) known involvement of TNF in the pathophysiology of chronic brain dysfunction in multiple diseases and disorders (review: ; 34, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62], Table 2); (2) the role of TNF in the pathophysiology of stroke, as discussed herein; (3) the existence of chronic, post-stroke intracerebral glial activation and neuroinflammation, as established by neuroimaging and pathological examination, as discussed herein; and (4) the known ability of etanercept to both rapidly neutralize pathologic TNF and reduce glial activation (Table 2) [45, 63, 64, 65, 66, 67].
Additionally, the novel clinical results reported, such as rapid improvement in vision and hearing, etc., may well be attributed to the fact that a potent biologic therapeutic (etanercept) is being administered by a novel route of administration (perispinal). Perispinal administration is designed to deliver etanercept into the cerebrospinal venous system as a method to enhance transport of etanercept across the blood–cerebrospinal fluid barrier [10, 16, 31, 35, 68, 69]. The unique anatomy and physiology of these interconnected venous plexuses is supported by a long series of experimental and pathological investigations recognized by those in the field, particularly in the neurosurgical community [10, 12, 14, 15, 16, 17, 18, 19, 27, 31, 35, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79].
2.8 Experimental Evidence
Experimental evidence, according to Hill, is where “the strongest support for the causation hypothesis may be revealed” . The experimental evidence supporting the use of perispinal etanercept for post-stroke neurological dysfunction is outlined in Table 2. The evidence, as reviewed in the previous and subsequent sections herein, can be separated into the following main categories:
2.8.1 Experimental Evidence in Multiple Models Suggests Pathologic Tumor Necrosis Factor (TNF) is Centrally Involved in the Pathophysiology of Stroke
Experimental evidence implicating TNF in stroke pathophysiology was published in 1994, and has continued through the present [80, 81, 82, 83, 84, 85, 86, 87, 88, 89]. A recent study investigated the long-term consequences of subarachnoid hemorrhage (SAH) on behavior, neuroinflammation, and damage to gray and white matter in Wistar rats through day 21 post-insult . Severe SAH induced significant gray- and white-matter damage and changes in multiple cytokines, including increased expression of TNF at 48 h post-insult . Neuroinflammation, including microglial activation, was “very long-lasting and still present at day 21” and accompanied by changes in sensorimotor behavior .
2.8.2 Experimental Evidence in Multiple Models Provides Data Demonstrating Improvement in Stroke Outcome Through Inhibition of TNF
TNF was identified as a mediator of post-stroke focal ischemic brain injury 2 decades ago [80, 81, 82, 89]. Specific inhibition of TNF, using antibodies or other recombinant TNF inhibitors, was found to reduce neurological damage from stroke, improving stroke outcomes [80, 81, 82, 88, 89].
Intracerebral hemorrhage is a devastating stroke subtype characterized by a prominent neuroinflammatory response. Antagonism of pro-inflammatory cytokines by specific antibodies represents a compelling therapeutic strategy to improve neurological outcome in patients after intracerebral hemorrhage … Post-injury treatment with the TNF-alpha antibody CNTO5048 resulted in less neuroinflammation and improved functional outcomes in a murine model of intracerebral hemorrhage …. TNF-alpha does not serve as a simple “biomarker” of inflammation, but rather plays a central role in mediating and extending neuronal injury after insult … Monoclonal antibodies against TNF-alpha make sense as a therapeutic strategy in intracerebral hemorrhage due to the marked neuroinflammatory effects seen in this disease .
Increased peri-hematomal expression of TNF has been functionally associated with neurovascular injury in multiple species and experimental models of intracerebral hemorrhage (ICH) [91, 92, 93, 94, 95, 96]. These findings are consistent with clinical reports that found elevated cerebrospinal fluid and plasma concentrations of TNF directly correlated with acute hematoma enlargement, edema development, and poor patient outcomes after ICH [97, 98, 99, 100, 101, 102]. In contrast to the early clinical success of biologic inhibitors, which directly bind TNF as a decoy receptor, small molecule inhibitors of TNF signaling pathways remain largely unexplored after ICH. TNF induces biological activity via stimulation of the TNF receptors (TNFR1 and TNFR2) [103, 104]. Post-ICH administration of R-7050, a novel cell-permeable triazoloquinoxaline compound that prevents the association of TNFR with intracellular adaptor molecules , reduced vasogenic edema and improved neurological outcomes in a mouse model of ICH . These studies raise the possibility that small molecule inhibitors of TNF-TNFR signaling may possess therapeutic potential after ICH.
A further mechanism to not only mitigate TNF-mediated actions and signaling after ICH but also to aid in defining their roles is to inhibit TNF generation. The controversial sedative, thalidomide, has immunomodulatory actions that are mediated, in large part, by lowering the rate of TNF synthesis [106, 107]. Recent analogs that more effectively achieve this include 3,6′-dithiothalidomide (3,6′-DT) , which readily enters the brain  and suppresses TNF synthesis post-transcriptionally at the level of translational regulation via the 3′-untranslated region of its messenger RNA (mRNA) [108, 110] as well as through down-regulation of the eukaryotic elongation initiation factor (eIF)-4E  to allow its rapid degradation.
In a mouse model of focal ischemic stroke in which brain TNF levels were found to be rapidly elevated within both ipsi- and contralateral brain, 3,6′-DT fully ameliorated this rise and reduced infarct volume, neuronal death, and neurological deficits . This neuroprotection was accompanied by reduced inflammation, with 3,6′-DT lowering the expression of interleukin (IL)-1Beta and inducible nitric oxide synthase, reducing activated microglia/macrophages, astrocyte, and neutrophil numbers, and decreasing the expression of intercellular adhesion molecule (ICAM)-1 within ischemic brain tissue . TNF plays a role in the induction of ICAM-1 expression and also promotes BBB leakage by inducing the expression of matrix metalloproteinase (MMP)-9 [113, 114], which degrades BBB tight junction proteins [115, 116]. Mitigating the rise in TNF by 3,6′-DT treatment suppressed the known TNF-induced activation of MMP-9  and, thereby, decreased stroke-induced BBB disruption by preserving junction proteins . In support of a major role of TNF in processes mediating stroke as well as TNF inhibition as the primary mechanism for the neuroprotective action of 3,6′-DT, the ability of 3,6′-DT to decrease ischemic brain damage was abolished in mice lacking TNF receptors .
The mechanisms underlying the detrimental effects of TNF signaling after ICH remain poorly defined and could provide additional therapeutic targets upon elucidation. Emerging data suggest that TNF induces necroptosis, a novel form of cell death with characteristic features of apoptosis, necrosis, and type 2 autophagic death [118, 119, 120, 121]. In an experimental model, hemorrhagic injury increased TNF expression and promoted necroptotic cell death in cultured glial cells . This effect was reversed by inhibition of receptor-interacting serine/threonine-protein kinase (RIPK)-1, a multi-functional protein kinase that interacts with TNFR to activate the pro-inflammatory transcription factor, nuclear factor (NF)-κB [123, 124, 125]. In line with this finding, it was observed that necrostatin-1, a pharmacological inhibitor of RIPK [124, 125], similarly limited neurovascular injury and improved outcomes in a pre-clinical model of ICH . This finding is also consistent with reports showing necrostatin-1 is neuroprotective in experimental models of ischemic stroke and TBI [125, 127, 128]. Taken together, these experimental results support the assertion that TNF induces detrimental effects after neurological injury and suggests that directed targeting of TNF and downstream signaling pathways may improve patient outcomes.
Additional research involving multiple animal models of stroke and TBI provides documentation of a favorable therapeutic response to TNF inhibition [42, 43, 44, 45, 60, 61, 81, 82, 86, 129]. As an example, brain TNF levels were found to have elevated rapidly (within 1 h) following concussive (weight drop-induced) mild TBI in mice, and were maximal at 12 h . Inhibition of this TBI-induced rise by administration of a single dose of the TNF synthesis inhibitor 3,6′-DT fully ameliorated cognitive impairments evaluated both 7 and 30 days later; supporting both a role for TNF in TBI-induced neuroinflammation/cognitive impairment and its targeting for treatment . Most recently, inhibition of phosphoinositide 3-kinase delta, a molecule that controls intracellular TNF trafficking in macrophages, was shown to reduce TNF secretion and neuroinflammation and confer protection in a mouse cerebral stroke model .
2.8.3 Positron Emission Tomographic Brain Imaging and Pathologic Evidence Demonstrate that Chronic Glial Activation and Neuroinflammation May Last for Years after Stroke and Other Forms of Acute Brain Injury
In 1988, researchers used autoradiography to investigate the effects of cerebral infarction induced by unilateral middle cerebral artery occlusion in rats. The radiolabeled ligand PK11195 that binds primarily to activated microglia was used. Seven days after stroke, [3H]PK11195 bound significantly in the cortical and striatal regions surrounding the focus of cerebral infarction with smaller increases in the ventrolateral and posterior thalamic complexes and in the substantia nigra, all ipsilateral to the occlusion .
In 1991, increased [3H]PK11195 binding in the thalamus during the second week after experimentally induced stroke in rats was found using ex vivo autoradiography, at a time when [3H]PK11195 binding around the primary lesion was beginning to subside .
In 2000, a multi-national European academic collaboration of neurologists, neuroscientists, and nuclear medicine specialists demonstrated that brain inflammation may persist for months or years after stroke in humans . The physicians and scientists investigated the potential of positron emission tomography (PET) using [11C]PK11195 to assess the microglial reaction in secondary thalamic lesions in patients with infarcts in the territory of the middle cerebral artery. All patients studied were found to have increased [11C]PK11195 binding in the ipsilateral thalamus, indicating microglial activation in projection areas remote from the primary lesion . The only patient studied more than 7 months after stroke was a 50-year-old patient with a primary stroke involving the left temporo-parietal region, and he demonstrated bilateral thalamic microglial activation 24 months after stroke .
In 2004, an international collaboration of neuroscientists found pathological evidence of a long-term intracerebral inflammatory response after TBI in a series of patients who had sustained blunt head injury. They described microglial hyperplasia and hypertrophy with major histocompatibility complex (MHC) class II upregulation, and inflammatory changes up to 16 years after the injury .
In 2005, Gerhard et al. , in another international collaboration of academic scientists and physicians, studied a series of patients between 3 and 150 days after onset of ischemic stroke in order to measure the time course of microglial activation. Utilizing (R)-[11C]-PK11195 PET, they found that brain inflammation was long-lasting after stroke, with (R)-[11C]-PK11195 binding involving both the area of the primary lesion and areas distant from the primary lesion site . They described the spread of the glial response beyond the ischemic core as closely resembling the progression of microglial activation in animal experiments, with “early recruitment of microglia in the ischemic border zone and later involvement of the neocortex and thalamus” .
In 2006, Price et al. , in a multi-center academic collaboration, used (R)-[11C]-PK11195 imaging to study a series of patients after stroke. Using this imaging methodology, they documented persistent neuroinflammation in the stroke penumbra and elsewhere in the brain in patients following stroke, and recognized that this neuroinflammatory response might represent a therapeutic opportunity that extends beyond time windows traditionally reserved for neuroprotection .
In 2011, Folkersma et al. , studied microglial activation in patients with moderate and severe TBI using (R)-[11C]-PK11195 brain PET, 6 months after trauma. In both whole-brain and regional analysis, increased (R)-[11C]-PK11195 binding potential was found compared with age- and sex-matched healthy controls. From these series, increased (R)-[11C]-PK11195 binding potential was found not only in the ipsilateral but also in the contralateral hemisphere, indicating prolonged and widespread microglia activation after TBI.
Subsequent studies, using either PET imaging or pathologic examination, have confirmed the existence of chronic intracerebral glial activation that has been documented to last for 17 years after even a single acute brain injury [138, 139].
Microglial imaging using (R)-[11C]-PK11195 brain PET can be of meaningful clinical and diagnostic value in terms of visualization and quantification of active neuroinflammatory and neurodegenerative disease processes and in elucidation of the long-term effects of neuroinflammatory sequelae and its implications for neurological outcome . Taken together, along with additional research showing that pathologic TNF mediates neurotoxicity in the ischemic penumbra, these data suggest that chronic microglial activation and neuroinflammation may be a common pathological response to stroke and other forms of acute brain injury [86, 133, 134, 135, 136, 137, 138, 139, 140].
There is a need to understand the long-term relationship between late microgliosis and TNF. Although the PET data discussed in this section do not describe TNF actions or changes, PET imaging before and after therapeutic intervention with TNF inhibitors that can quantify and describe patterns of microglial activation promises to be a fertile area for future investigation. As suggested by Price et al. , the accumulating evidence indicates that chronic glial activation after acute brain injury represents a therapeutic target that persists far longer than the time windows traditionally reserved for neuroprotection. This evidence provides a scientific basis for considering pharmacologic therapeutic intervention that targets chronic glial activation months or years after stroke, and supports the plausibility of achieving a therapeutic response in patients with chronic post-stroke neurological dysfunction by targeting pathologic TNF concentration [86, 133, 134, 135, 136, 137, 138, 139].
2.8.4 Experimental Evidence Implicates TNF in the Neurotoxicity Produced by Glial Activation in the Stroke Penumbra
In an in vitro model of microglial activation and propagated neuron killing in the stroke penumbra, TNF inhibition using a soluble TNF receptor reduced neurotoxicity . In addition, experimental data suggest that TNF functions as a gliotransmitter that is involved in the mechanisms whereby glia modulate synaptic transmission and neuronal network function [141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155].
2.8.5 Etanercept is Both a Potent TNF Inhibitor and an Inhibitor of Microglial Activation
The plausibility of beneficial effects of etanercept for treatment of chronic post-stroke neurological dysfunction is supported by the fact that, in addition to its known role as a potent biologic inhibitor of TNF, etanercept has also been shown to be capable of reducing glial activation in multiple experimental models [45, 64, 65, 66, 67]. The known physiological effects of etanercept on TNF and glial activation make it a well matched candidate to address the chronic glial activation and pathologic TNF that may be a long-lasting consequence of stroke [45, 64, 65, 66, 67, 86, 133, 135, 136].
Review of the medical literature provides evidence supporting the plausibility of the results of the etanercept stroke studies by analogy, as discussed below.
2.9.1 Etanercept and Other Biologic TNF Inhibitors Reduce Neuropathic Pain
Statistically significant improvements in pain, including improvements in hyperesthesia, allodynia, pain associated with spasticity, post-stroke shoulder pain, and neuropathic pain were reported in the 617-patient stroke cohort . These results are supported by a long series of experiments documenting the effects of etanercept and other biologic TNF inhibitors in experimental models and in the clinic.
In 1998 and thereafter, Sommer and colleagues [156, 157, 158], in a series of basic science experiments, demonstrated the central involvement of TNF in the pathophysiology of neuropathic pain and the favorable effects of anti-TNF antibody treatment in these models. In 1999, a separate group of investigators  showed that neuropathic pain was mediated by brain-derived TNF. Subsequent studies provided further supportive evidence [159, 160, 161, 162, 163, 164, 165]. In 2001, etanercept was shown to reduce hyperalgesia in experimental painful neuropathy . In 2003 and 2004, the first human evidence of the effectiveness of etanercept for treating neurological spinal pain was published [167, 168, 169, 170]. Many of these early studies were performed by the authors and their colleagues. Subsequently, four randomized controlled clinical trials have provided favorable data supporting the efficacy of etanercept for neurological spinal pain, and TNF inhibition is emerging as a treatment strategy for intractable sciatica and other forms of intervertebral disc-related pain [171, 172, 173, 174, 175, 176]. The accumulated evidence is substantial [65, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 177, 178, 179]. This evidence, taken together, suggests by analogy the plausibility of pain improvement following etanercept in patients with chronic post-stroke pain.
2.9.2 TNF is Centrally Involved in the Pathophysiology of Chronic Brain Dysfunction in Multiple Disease States
Statistically significant reduction in cognitive impairment is reported in the 617-patient stroke cohort following perispinal etanercept treatment . The data included improvement in a standardized instrument, the Montreal Cognitive Assessment, with p-values less than 0.0001 immediately post-treatment and 1 and 3 weeks later . The cognitive improvement documented in the etanercept stroke studies is supported, by analogy, by substantial scientific evidence that suggests that TNF is centrally involved in the pathophysiology of chronic brain dysfunction.
Beginning in the 1980s, and continuing into the present, TNF has been implicated in the pathophysiology of multiple diseases and disorders associated with chronic brain dysfunction, including cerebral malaria [32, 51, 56, 180, 181, 182, 183, 184, 185]; TBI [45, 52, 60, 61, 129, 186, 187]; Alzheimer’s disease [32, 34, 53, 55, 59, 149, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203], frontotemporal dementia ; primary progressive aphasia [62, 204]; sarcoidosis ; rheumatoid arthritis ; surgery-induced cognitive decline ; and a wide variety of additional diseases and disorders [32, 58, 67, 207]. For example, an increasing body of evidence supports a major role for central neuroinflammatory mechanisms in the pathogenesis of hepatic encephalopathy, a neuropsychiatric complication of both acute and chronic liver failure. Microglial activation in liver failure has been attributed to the accumulation of lactate in the brain, and focal accumulation of brain lactate is a common feature of stroke, TBI, and status epilepticus, conditions that are known to result in significant neuroinflammation [67, 208]. Neuroinflammation characterized by microglial activation and increased expression of pro-inflammatory cytokines in the brain has been reported in both human and experimental liver failure of diverse etiology, including viral hepatitis  and biliary cirrhosis , as well as in acute liver failure resulting from toxic  or ischemic  liver injuries. Microglial activation and increased pro-inflammatory cytokine expression are significantly correlated with the grade of encephalopathy in these disorders. Moreover, slowing of hepatic encephalopathy progression has been demonstrated following inhibition of microglial activation by hypothermia  or minocycline  and following the use of anti-TNF strategies such as etanercept . TNFR gene deletion delays the progression of hepatic encephalopathy in mice with acute liver failure resulting from toxic liver injury .
2.9.3 Infusion of Recombinant Human TNF Produced Focal Neurological Dysfunction in Early Human Studies, Supporting a Role of Excess TNF in the Pathogenesis of Such Disorders
Two elderly patients had transient episodes of focal neurological deficits. One patient had an isolated loss of recent memory, while the other had transient expressive aphasia. No abnormalities were noted upon computerized tomography brain scan or cerebrospinal fluid analysis. In each case, the symptoms occurred near the completion of treatment and resolved without sequelae within 6 h. These two toxic events occurred at doses of 182 and 327 μg/m2 and did not represent dose-limiting toxicity .
These early cases of focal neurological toxicity following TNF infusion provide further scientific support for the involvement of excess TNF in the pathophysiology of post-stroke neurological dysfunction and the perispinal etanercept results.
2.9.4 Specific Evidence Suggests that Etanercept has the Potential to Reduce Cognitive Impairment in Multiple Disorders Associated with Chronic Brain Dysfunction
Etanercept has demonstrated favorable effects in neuroinflammatory disorders, both in the clinic and in multiple experimental models [4, 5, 10, 35, 45, 58, 60, 61, 64, 65, 66, 67, 68, 69, 146, 166, 167, 168, 169, 170, 171, 172, 173, 177, 178, 179, 204, 207, 216, 217, 218, 219, 220, 221].
TNF levels in the cerebrospinal fluid 25 times higher than in controls have been found in patients with Alzheimer’s disease . In patients with mild cognitive impairment (MCI) followed prospectively, “only MCI patients who progressed to Alzheimer’s disease at follow up, showed significantly higher CSF levels of TNF-alpha than controls … Indicating that CNS inflammation is a early hallmark in the pathogenesis of AD” . A later study from these investigators supported this conclusion regarding the role of TNF in Alzheimer’s disease pathogenesis .
In 2006, the clinical results of a prospective, single-center, open-label, pilot clinical trial of perispinal etanercept for Alzheimer’s disease was reported by the senior author and colleagues . The authors included two neurologists, a rheumatologist, and an internist, and the study included 15 patients treated with perispinal etanercept weekly over a period of 6 months . The main outcome measures included three standard instruments for measuring cognition: the Mini-Mental State Examination (MMSE), the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog), and the Severe Impairment Battery (SIB). There was significant improvement with treatment, as measured by all of the primary efficacy variables, through 6 months: MMSE increased by 2.13 ± 2.23 (p < 0.003), ADAS-Cog improved (decreased) by 5.48 ± 5.08 (p < 0.006), and SIB increased by 16.6 ± 14.52 (p < 0.04).
In 2008, rapid cognitive improvement in a patient with Alzheimer’s disease following treatment with perispinal etanercept was reported by the senior author and a neurologist . Sue Griffin, co-editor of the Journal of Neuroinflammation, reported her independent observations after witnessing rapid clinical improvement in additional patients with Alzheimer’s disease following treatment with perispinal etanercept . Subsequent publications by the senior author and colleagues documented cognitive improvement in patients with Alzheimer’s disease and other forms of dementia following treatment with perispinal etanercept [10, 68, 69, 146, 204, 219].
In a basic science study conducted by the senior author and Stanford scientists and published in 2009, perispinal administration of radiolabeled etanercept followed by head-down positioning was discovered to deliver radiolabeled etanercept into the choroid plexus and cerebrospinal fluid within the cerebral ventricles within minutes of injection, as visualized by PET scan .
In 2010, Chio et al.  studied etanercept in an experimental model of TBI. They found that etanercept caused attenuation of TBI-induced cerebral ischemia, reduction of motor and cognitive function deficits, and reduction of microglial activation .
Chen et al.  studied the effects of anti-TNF treatment on cognition in 15 patients with rheumatoid arthritis over a period of 6 months with subcutaneous anti-TNF treatment: eight received etanercept 25 mg twice weekly and seven received adalimumab 40 mg twice monthly. Cognitive function determined by MMSE scores was significantly improved in the patient cohort .
Elfferich et al.  studied 343 sarcoidosis patients over a period of 6 months, with all patients completing the Cognitive Failure Questionnaire (CFQ) at baseline and at 6 months . Patients were separated into three groups: (1) no immunomodulating drugs; (2) prednisone with or without methotrexate; and (3) anti-TNF drugs. Only patients receiving anti-TNF drugs demonstrated a significant improvement in CFQ score .
Chou et al.  presented the results of their review of medical and pharmacy claims data from January 2000 to November 2007 for a commercially insured cohort of 8.5 million adults throughout the USA. They derived a sub-cohort of 42,193 patients with a pre-existing diagnosis of rheumatoid arthritis. In this population of adults with rheumatoid arthritis, they found a 55 % decreased incidence in Alzheimer’s in those patients treated with TNF inhibitors, but not with other disease-modifying agents used for treatment of rheumatoid arthritis . When they further analyzed the risk according to the individual anti-TNF agent used, they found that only etanercept was significantly (p = 0.024) associated with reduced risk .
In 2011, Shi et al. [195, 196] reported cognitive improvement in a woman with Alzheimer’s disease following intrathecal administration of infliximab, a chimeric TNF monoclonal antibody, following the favorable results of the use of infliximab in an experimental Alzheimer’s model [195, 196].
In 2012, Gabbita et al.  found that early intervention with a small molecule inhibitor of TNF prevented cognitive deficits and improved the ratio of resting to reactive microglia in the hippocampus in a murine triple transgenic model of Alzheimer’s disease. Belarbi et al.  found that a TNF protein synthesis inhibitor restored neuronal function and reversed cognitive deficits induced by chronic neuroinflammation. McNaull et al. [197, 229] and Butchart and Holmes [197, 229] discussed the rationale for TNF inhibition as a treatment approach for Alzheimer’s disease in their review articles [197, 229].
Bassi and De Filippi  reported verbal, cognitive, and behavioral improvement in a patient with long-standing neurological dysfunction, in whom etanercept was used for treatment of psoriasis. The beneficial effect on cognition and social interaction was a surprising side effect of etanercept used to treat the cutaneous psoriasis .
In 2013, Cheong et al. [197, 229] studied etanercept in an experimental model of TBI. They found that neurological and motor deficits, cerebral contusion, and increased brain TNF-alpha contents caused by TBI were attenuated by etanercept .
In 2014, Detrait et al. [197, 229] reported favorable effects of etanercept administered systemically in a basic science Alzheimer’s model . However, the only dose that was effective across all measures of efficacy was the highest dose, 30 mg/kg given every 2 days (for a total dose of 90 mg/kg given during the first week). This 90-mg/kg weekly dose is more than 100 times the normal human etanercept dose. Etanercept doses of 3 mg/kg every 2 days, about 15 times the usual human dose, were not effective. The lack of efficacy of systemically administered etanercept in this Alzheimer’s disease model at doses closer to the usual human therapeutic dose is consistent with a previous Alzheimer’s disease clinical trial in which etanercept administered systemically at a dose of 25 mg twice weekly was not found to be effective .
The totality of this evidence suggests, by analogy, the plausibility of cognitive improvement following perispinal administration of etanercept in patients with chronic post-stroke cognitive impairment.
2.9.5 Independent Eye-Witness Observations
Finally, rapid neurological improvement following perispinal etanercept has been witnessed first-hand by independent third parties, including several of the authors of this commentary as well as others [11, 35, 216, 217, 232]. A new report has documented that a single dose of perispinal etanercept produced an immediate, profound, and sustained improvement in expressive aphasia, speech apraxia, cognitive dysfunction, and left hemiparesis in a patient with chronic, intractable, debilitating neurological dysfunction present for more than 3 years after acute brain injury . Replication of experimental results with validation by different observers is a time-honored cardinal scientific principle supporting the reliability of a scientific observation .
In summary, perispinal etanercept for post-stroke neurological and cognitive dysfunction satisfies all of Hill’s nine criteria: strength of the association; consistency; specificity; temporality; biological gradient; biological plausibility; coherence; experimental evidence; and analogy.
The Oxford Centre for Evidence-Based Medicine (OCEBM) is widely regarded as an authority in the development of evidence-ranking schemes in medicine . OCEBM documents “a growing recognition that observational studies—even case-series and anecdotes can sometimes provide definitive evidence” and allows for “observational studies with dramatic effects to be ‘upgraded’” with respect to level of evidence. The current evidence hierarchy standard promulgated by the OCEBM ranks observational studies that demonstrate dramatic effects as level 2 evidence . The etanercept stroke studies, each of which documents dramatic clinical improvement following perispinal etanercept administration, therefore provide level 2 evidence of the effectiveness of perispinal etanercept for post-stroke neurological dysfunction [233, 234, 235, 236]. The weight of the evidence calls for the initiation and funding of the exceedingly costly, large-scale, randomized controlled trials necessary to obtain US FDA approval of perispinal etanercept for these indications. The cost of clinical trials for brain disorders can exceed $US1 billion . Until such trials are completed, the elaborated evidence and unmet medical need provide an ethical mandate that together support this off-label treatment approach [33, 40, 238, 239, 240, 241, 242, 243, 244, 245, 246]. With the additional weight of recent basic science studies reporting favorable effects of etanercept in a diverse group of brain disorders, and scientists from several independent academic centers reporting favorable effects of TNF inhibition in other stroke models, now is the time to seriously consider systematic testing of perispinal etanercept for brain injury, especially in stroke. Clinical trials should be directed at early and late post-stroke interventions that can validate the drug for potential future use.
4 Future Directions
“[T]here is clearly a need to “do things differently” if there is to be a major advance in the development of new interventions … We need to scan the scientific landscape to embrace new ideas and approaches … Be alert to new models of disease that may vertically integrate basic, clinical, and epidemiological disciplines. For example, could advances in the understanding of infectious disease or inflammation dramatically change our thinking about stroke pathogenesis?” 
Scientific communities do not easily embrace new ideas, despite the calls of its leaders to do so [3, 36, 247, 248, 249, 250, 251, 252]. As Wolinsky has stated, “the advancement of scientific knowledge is an uphill struggle against ‘accepted wisdom’” . Recognition that chronic microglial activation, synaptic plasticity, and pathologic TNF concentration are therapeutic targets that may be therapeutically addressed for years following stroke and other forms of acute brain injury provides an exciting new direction for research and treatment.
Acknowledgments and Conflict Disclosure
None of the authors received funding for writing this paper. Authors Butterworth, Folkersma, and Dhandapani have no conflicts of interest. The authors thank Nigel Grieg and David Tweedie, both from the Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, Baltimore, Maryland, for their contributions to the text in the sections describing the experimental results of thalidomide analogs. Edward Tobinick has multiple issued and pending US and foreign patents, assigned to TACT IP, LLC, that claim methods of use of etanercept for treatment of neurological disorders, including but not limited to US patents 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, and 8349323, all assigned to TACT IP, LLC; and Australian patent 758523. Dr. Tobinick is the founder of the Institute of Neurological Recovery, a group of medical practices that utilize perispinal etanercept as a therapeutic modality, and also train physicians; and he is the CEO of TACT IP, LLC. Tracey Ignatowski and Robert Spengler have been unpaid expert witnesses for the INR. Tracey Ignatowski and Robert Spengler’s professional activities include their work as co-directors of neuroscience at NanoAxis, LLC, a company formed to foster the commercial development of products and applications in the field of nanomedicine that include novel methods of inhibiting TNF. The article represents the authors’ own work in which NanoAxis, LLC was not involved.
- 17.Tubbs RS, Hansasuta A, Loukas M, Louis RG Jr, Shoja MM, Salter EG, et al. The basilar venous plexus. Clin Anat. 2007;20(7):755–9.Google Scholar
- 18.Nathoo N, Caris EC, Wiener JA, Mendel E. History of the vertebral venous plexus and the significant contributions of Breschet and Batson. Neurosurgery. 2011;69(5):1007-14; discussion 14.Google Scholar
- 23.Morimoto A, Takase I, Shimizu Y, Nishi K. Assessment of cervical venous blood flow and the craniocervical venus valve using ultrasound sonography. Leg Med. 2009;11(1):10–7.Google Scholar
- 25.Dabus G, Batjer HH, Hurley MC, Nimmagadda A, Russell EJ. Endovascular treatment of a bilateral dural carotid-cavernous fistula using an unusual unilateral approach through the basilar plexus. World Neurosurg. 2012;77(1):201 e5–8.Google Scholar
- 28.Puri AS, Telischak NA, Vissapragada R, Thomas AJ. Analysis of venous drainage in three patients with extradural spinal arteriovenous fistulae at the craniovertebral junction with potentially benign implication. J Neurointerv Surg. 2014;6(2):105-5Google Scholar
- 30.Griessenauer CJ, Raborn J, Foreman P, Shoja MM, Loukas M, Tubbs RS. Venous drainage of the spine and spinal cord: A comprehensive review of its history, embryology, anatomy, physiology, and pathology. Clin Anat. 2014 Feb 22 [Epub ahead of print].Google Scholar
- 37.Hill AB. The environment and disease: association or causation? Proc Royal Soc Med. 1965;58:295–300.Google Scholar
- 39.See A. Use of human epidemiology studies in proving causation. Def Counsel J. 2000;67:478–87.Google Scholar
- 43.Lei B, Dawson HN, Roulhac-Wilson B, Wang H, Laskowitz DT, James ML. Tumor necrosis factor alpha antagonism improves neurological recovery in murine intracerebral hemorrhage. J Neuroinflamm. 2013;10(1):103.Google Scholar
- 44.Works MG, Koenig JB, Sapolsky RM. Soluble TNF receptor 1-secreting ex vivo-derived dendritic cells reduce injury after stroke. J Cereb Blood Flow Metab. 2013;33(9):1376-85.Google Scholar
- 50.Pettygrove S. Dose-response relationship. Encycl Epidemiol. 2008;1:282–3.Google Scholar
- 57.Terrando N, Monaco C, Ma D, Foxwell BM, Feldmann M, Maze M. Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci U S A. 2010;107(47):20518-22.Google Scholar
- 67.Butterworth RF. The liver-brain axis in liver failure: neuroinflammation and encephalopathy. Nat Rev Gastroenter Hepatol. 2013;10(9):522–8.Google Scholar
- 70.Breschet G. Essai sur les veines du rachis [Theses presentees et soutenues publiq. devant les juges concours le 28. Avril 1819]. Paris: Faculte de Medecine de Paris; 1819.Google Scholar
- 71.Breschet G. Recherches anatomiques physiologiques et pathologiques sur le systáeme veineux. Paris: Rouen fráeres; 1829. p. 48.Google Scholar
- 72.Gray H, Holmes T. Anatomy, descriptive and surgical. 4th ed. London: Longmans, Green, and Co.; 1866.Google Scholar
- 73.Quain J. The elements of anatomy, 7 ed. 7th ed. London: James Walton; 1867.Google Scholar
- 75.Netter FH, Ciba Pharmaceutical Products inc., CIBA-GEIGY Corporation. The Ciba collection of medical illustrations : a compilation of pathological and anatomical paintings. Summit (NJ): Ciba Pharmaceutical Products; 1958.Google Scholar
- 78.Groen RJ, du Toit DF, Phillips FM, Hoogland PV, Kuizenga K, Coppes MH, et al. Anatomical and pathological considerations in percutaneous vertebroplasty and kyphoplasty: a reappraisal of the vertebral venous system. Spine (Phila Pa 1976). 2004;29(13):1465–71.Google Scholar
- 79.Griessenauer CJ, Raborn J, Foreman P, Shoja MM, Loukas M, Tubbs RS. Venous drainage of the spine and spinal cord: a comprehensive review of its history, embryology, anatomy, physiology, and pathology. Clin Anat. 2014 Feb 22 [Epub ahead of print].Google Scholar
- 83.Zaremba J. Contribution of tumor necrosis factor alpha to the pathogenesis of stroke. Folia Morphol (Warsz). 2000;59(3):137–43.Google Scholar
- 87.Siniscalchi A, Gallelli L, Malferrari G, Pirritano D, Serra R, Santangelo E, et al. Cerebral stroke injury: the role of cytokines and brain inflammation. J Basic Clin Physiol Pharmacol. 2014;25(2):131-7.Google Scholar
- 96.Wasserman JK, Zhu X, Schlichter LC. Evolution of the inflammatory response in the brain following intracerebral hemorrhage and effects of delayed minocycline treatment. Brain Res. 2007;1180:140-54.Google Scholar
- 102.Hua Y, Wu J, Keep RF, Nakamura T, Hoff JT, Xi G. Tumor necrosis factor-alpha increases in the brain after intracerebral hemorrhage and thrombin stimulation. Neurosurgery. 2006;58(3):542–50; discussion -50.Google Scholar
- 117.Takata F, Dohgu S, Matsumoto J, Takahashi H, Machida T, Wakigawa T, et al. Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-α, releasing matrix metalloproteinase-9 and migrating in vitro. J Neuroinflammation. 2011;8(106):1–12.Google Scholar
- 126.King MD, Whitaker-Lea WA, Campbell J, Alleyne CH, Dhandapani KM. Necrostatin-1 reduces neurovascular injury after intracerebral hemorrhage. Int J Cell Biol. 2014 Mar 6 [Epub ahead of print]Google Scholar
- 136.Price CJ, Wang D, Menon DK, Guadagno JV, Cleij M, Fryer T, et al. Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. Stroke J Cereb Circ. 2006;37(7):1749–53.Google Scholar
- 139.Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain J Neurol. 2013;136(Pt 1):28–42.Google Scholar
- 147.Wang Y. P4-266: Modification of synaptic plasticity by TNF and sphingomyelinase: Implications for cognitive impairment in Alzheimer’s disease. Alzheimer Dement. 2008;4(4 Supplement):T749.Google Scholar
- 151.Cavanagh C, Colby-Milley J, Farso M, Krantic S, Quirion R. Early molecular and synaptic dysfunctions in the prodromal stages of Alzheimer’s disease: focus on TNF-alpha and IL-1Beta. Future Neurol. 2011;6(6):757–69.Google Scholar
- 155.Faingold CL. Chapter 7: network control mechanisms: cellular inputs, neuroactive substances, and synaptic changes. In: Faingold CL, Blumenfeld H, editors. Neuronal Networks in Brain Function, CNS Disorders, and Therapeutics. Elsevier; 2014.Google Scholar
- 163.Ignatowski TA, Spengler RN II. Cytokines in the brain, B. cytokines in brain physiology: cytokines in synaptic function. In: Phelps C, Korneva E, editors. NeuroImmune biology, Vol 6: Cytokines and the brain. Amsterdam: Elsevier; 2008. p. 111–44.Google Scholar
- 165.Ignatowski TA, Gerard BA, Bonoiu AC, Mahajan S, Knight PR, Davidson BA, et al., editors. Reduction of tumor necrosis factor (TNF) in the hippocampus alleviates neuropathic pain perception. In: Proceedings of the 4th International Congress on Neuropathic Pain, 2013. p. 29–35..Google Scholar
- 172.Ohtori S, Miyagi M, Eguchi Y, Inoue G, Orita S, Ochiai N, et al. Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study. Spine (Phila Pa 1976). 2012;37(6):439–44.Google Scholar
- 173.Freeman BJ, Ludbrook GL, Hall S, Cousins M, Mitchell B, Jaros M, et al. Randomized, double-blind, placebo-controlled, trial of transforaminal epidural etanercept for the treatment of symptomatic lumbar disc herniation. Spine (Phila Pa 1976). 2013;38(23):1986–94.Google Scholar
- 174.Kaufman EL, Carl A. Biochemistry of back pain. Open Spine J. 2013;5:12–8.Google Scholar
- 175.Sainoh T, Orita S, Yamauchi K, Suzuki M, Sakuma Y, Kubota G, et al. Intradiscal administration of tumor necrosis factor-alpha inhibitor, etanercept, clinically improves intractable discogenic low back pain: a prospective randomized study. In: International society for the study of the lumbar spine 40th annual meeting; Scottsdale (AZ); 2013.Google Scholar
- 176.Winkelstein BA, Allen KD, Setton LA. Chapter 19: intervertebral disc herniation: pathophysiology and emerging therapies. In: Shapiro IM, Risbud MV, editors. The intervertebral disc. Wien: Springer; 2014.Google Scholar
- 177.Zanella JM, Burright EN, Hildebrand K, Hobot C, Cox M, Christoferson L, et al. Effect of etanercept, a tumor necrosis factor-alpha inhibitor, on neuropathic pain in the rat chronic constriction injury model. Spine (Phila Pa 1976). 2008;33(3):227–34.Google Scholar
- 179.Coelho SC, Bastos-Pereira AL, Fraga D, Chichorro JG, Zampronio AR. Etanercept reduces thermal and mechanical orofacial hyperalgesia following inflammation and neuropathic injury. Eur J Pain. 2014 Jan 7 [Epub ahead of print].Google Scholar
- 191.Medeiros R, Prediger RD, Passos GF, Pandolfo P, Duarte FS, Franco JL, et al. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer’s disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci. 2007;27(20):5394–404.PubMedGoogle Scholar
- 197.Butchart J, Holmes C. Systemic and central immunity in alzheimer’s disease: therapeutic implications. CNS Neurosci Ther. 2012;18(1):64-76.Google Scholar
- 199.Williams M, Coyle JT. Chapter 7: Historical perspectives on the discovery and development of drugs to treat neurological disorders. In: Barrett JE, Coyle JT, Williams M, editors. Translational neuroscience: applications in psychiatry, neurology, and neurodevelopmental disorders. Cambridge: Cambridge University Press; 2012. p. 129–48.Google Scholar
- 217.Griffin WS. Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflamm. 2008;5:3.Google Scholar
- 218.Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J Neuroinflamm. 2008;5:2.Google Scholar
- 225.Chou RC, Kane MA, Ghimire S, Gautam S. Tumor necrosis factor inhibition reduces the incidence of Alzheimer’s disease in rheumatoid arthritis patients. In: American College of Rheumatology Annual Meeting, presentation 6402010.Google Scholar
- 226.Walsh N. ACR: Anti-TNF drugs may protect against Alzheimer’s. Medpage Today. 2010;9:2010.Google Scholar
- 227.Gabbita SP, Srivastava MK, Eslami P, Johnson MF, Kobritz NK, Tweedie D, et al. Early intervention with a small molecule inhibitor for tumor necrosis factor-alpha prevents cognitive deficits in a triple transgenic mouse model of Alzheimer’s disease. J Neuroinflamm. 2012;9:99.Google Scholar
- 228.Belarbi K, Jopson T, Tweedie D, Arellano C, Luo W, Greig NH, et al. TNF-alpha protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. J Neuroinflamm. 2012;9:23.Google Scholar
- 230.Detrait ER, Danis B, Lamberty Y, Foerch P. Peripheral administration of an anti-TNF-alpha receptor fusion protein counteracts the amyloid induced elevation of hippocampal TNF-alpha levels and memory deficits in mice. Neurochem Int. 2014;72C:10-13.Google Scholar
- 231.Bohac D, Burke W, Cotter R, Zheng J, Potter J, Gendelman H. A 24-week randomized, double-blind, placebo-controlled study of the efficacy and tolerability of TNFR: Fc (etanercept) in the treatment of dementia of the Alzheimer type. Neurobiol Aging. 2002;23(1: Supplement 1):S1-S606, abstract 315.Google Scholar
- 232.Neurex. Meeting on the roles of TNF in brain dysfunction and disease. Basel; 2012.Google Scholar
- 233.OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653 [Internet]. 2011.
- 238.Guidance for off-label use of drugs. Lancet neurology. 2008;7(4):285Google Scholar
- 239.Frattarelli DA, Galinkin JL, Green TP, et al. Off-label use of drugs in children. Pediatrics. 2014;133(3):563-7Google Scholar
- 240.American Psychiatric Association. The principles of medical ethics: with annotations especially applicable to psychiatry. 2001st ed. Washington, D.C.: American Psychiatric Association; 2001. p. 46.Google Scholar
- 248.Zivin JA, Simmons JG. tPA for stroke: the story of a controversial drug. Oxford: Oxford University Press; 2010.Google Scholar
- 250.Kuhn TS. The structure of scientific revolutions. Chicago: University of Chicago Press; 1962. xv, p. 172.Google Scholar
- 251.Kuhn TS, Conant J, Haugeland J. The road since structure: philosophical essays, 1970–1993, with an autobiographical interview. Chicago: University of Chicago Press; 2000. viii, p. 335.Google Scholar
- 252.Bauer HH. Dogmatism in science and medicine: how dominant theories monopolize research and stifle the search for truth. Jefferson (NC): McFarland & Co., Inc., Publishers; 2012. vii, p. 293.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.